PT  - JOURNAL ARTICLE
AU  - ONDREJ FIALA
AU  - MILOS PESEK
AU  - JINDRICH FINEK
AU  - ONDREJ TOPOLCAN
AU  - JAROSLAV RACEK
AU  - MARTIN SVATON
AU  - RADEK KUCERA
AU  - MAREK MINARIK
AU  - LUCIE BENESOVA
AU  - ZBYNEK BORTLICEK
AU  - RENATA CHLOUPKOVA
AU  - ALEXANDR POPRACH
AU  - TOMAS BUCHLER
TI  - Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib
DP  - 2016 May 01
TA  - Anticancer Research
PG  - 2459--2465
VI  - 36
IP  - 5
4099  - http://ar.iiarjournals.org/content/36/5/2459.short
4100  - http://ar.iiarjournals.org/content/36/5/2459.full
SO  - Anticancer Res2016 May 01; 36
AB  - Background: Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. Patients and Methods: Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment. Results: The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001). Conclusion: LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC.